Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-α

Jorge Cortes, Francis Giles, Susan O'Brien, Deborah Thomas, Guillermo Garcia-Manero, Mary Beth Rios, Stefan Faderl, Srdan Verstovsek, Alessandra Ferrajoli, Emil J. Freireich, Moshe Talpaz, Hagop Kantarjian

Research output: Contribution to journalArticle

Abstract

Imatinib at 400 mg daily is effective in chronic-phase chronic myeloid leukemia (CML) after interferon failure, although only a few patients achieve a molecular remission. We investigated whether higher doses of imatinib may be more effective. Thirty-six patients with chronic-phase CML after failure on interferon-α were treated with 400 mg imatinib twice daily. Median time from diagnosis was 25 months (range, 10-135 months); 4 patients (11%) had clonal evolution. All 11 patients with active disease achieved complete hematologic response. Excluding patients with fewer than 35% Ph-positive metaphases before the start of therapy, 19 (90%) of 21, evaluable patients achieved a major cytogenetic response. Of 27 evaluable patients, 24 (89%) achieved a complete cytogenetic response. Quantitative polymerase chain reaction was performed in bone marrow every 3 months. Of 32 evaluable patients, 18 (56%) showed BCR-ABL/ABL percentage ratios lower than 0.045%, including 13 (41%) with undetectable levels. With a median follow-up of 15 months, all patients were alive in chronic phase. Toxicities were similar to those reported with standard dose; 71% of patients continue to receive 600 mg or more of imatinib daily. In conclusion, high-dose imatinib induces complete cytogenetic responses, in most patients with chronic-phase CML after interferon failure. This is accompanied by a high rate of molecular remission.

Original languageEnglish (US)
Pages (from-to)83-86
Number of pages4
JournalBlood
Volume102
Issue number1
DOIs
StatePublished - Jul 1 2003

Fingerprint

Philadelphia Chromosome
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chromosomes
Interferons
Leukemia, Myeloid, Chronic Phase
Cytogenetics
Polymerase chain reaction
Toxicity
Bone
Imatinib Mesylate
Clonal Evolution
Metaphase
Bone Marrow

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-α. / Cortes, Jorge; Giles, Francis; O'Brien, Susan; Thomas, Deborah; Garcia-Manero, Guillermo; Rios, Mary Beth; Faderl, Stefan; Verstovsek, Srdan; Ferrajoli, Alessandra; Freireich, Emil J.; Talpaz, Moshe; Kantarjian, Hagop.

In: Blood, Vol. 102, No. 1, 01.07.2003, p. 83-86.

Research output: Contribution to journalArticle

Cortes, J, Giles, F, O'Brien, S, Thomas, D, Garcia-Manero, G, Rios, MB, Faderl, S, Verstovsek, S, Ferrajoli, A, Freireich, EJ, Talpaz, M & Kantarjian, H 2003, 'Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-α', Blood, vol. 102, no. 1, pp. 83-86. https://doi.org/10.1182/blood-2003-01-0025
Cortes, Jorge ; Giles, Francis ; O'Brien, Susan ; Thomas, Deborah ; Garcia-Manero, Guillermo ; Rios, Mary Beth ; Faderl, Stefan ; Verstovsek, Srdan ; Ferrajoli, Alessandra ; Freireich, Emil J. ; Talpaz, Moshe ; Kantarjian, Hagop. / Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-α. In: Blood. 2003 ; Vol. 102, No. 1. pp. 83-86.
@article{88c316f3aa8b4044b3ec936981a150be,
title = "Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-α",
abstract = "Imatinib at 400 mg daily is effective in chronic-phase chronic myeloid leukemia (CML) after interferon failure, although only a few patients achieve a molecular remission. We investigated whether higher doses of imatinib may be more effective. Thirty-six patients with chronic-phase CML after failure on interferon-α were treated with 400 mg imatinib twice daily. Median time from diagnosis was 25 months (range, 10-135 months); 4 patients (11{\%}) had clonal evolution. All 11 patients with active disease achieved complete hematologic response. Excluding patients with fewer than 35{\%} Ph-positive metaphases before the start of therapy, 19 (90{\%}) of 21, evaluable patients achieved a major cytogenetic response. Of 27 evaluable patients, 24 (89{\%}) achieved a complete cytogenetic response. Quantitative polymerase chain reaction was performed in bone marrow every 3 months. Of 32 evaluable patients, 18 (56{\%}) showed BCR-ABL/ABL percentage ratios lower than 0.045{\%}, including 13 (41{\%}) with undetectable levels. With a median follow-up of 15 months, all patients were alive in chronic phase. Toxicities were similar to those reported with standard dose; 71{\%} of patients continue to receive 600 mg or more of imatinib daily. In conclusion, high-dose imatinib induces complete cytogenetic responses, in most patients with chronic-phase CML after interferon failure. This is accompanied by a high rate of molecular remission.",
author = "Jorge Cortes and Francis Giles and Susan O'Brien and Deborah Thomas and Guillermo Garcia-Manero and Rios, {Mary Beth} and Stefan Faderl and Srdan Verstovsek and Alessandra Ferrajoli and Freireich, {Emil J.} and Moshe Talpaz and Hagop Kantarjian",
year = "2003",
month = "7",
day = "1",
doi = "10.1182/blood-2003-01-0025",
language = "English (US)",
volume = "102",
pages = "83--86",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "1",

}

TY - JOUR

T1 - Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-α

AU - Cortes, Jorge

AU - Giles, Francis

AU - O'Brien, Susan

AU - Thomas, Deborah

AU - Garcia-Manero, Guillermo

AU - Rios, Mary Beth

AU - Faderl, Stefan

AU - Verstovsek, Srdan

AU - Ferrajoli, Alessandra

AU - Freireich, Emil J.

AU - Talpaz, Moshe

AU - Kantarjian, Hagop

PY - 2003/7/1

Y1 - 2003/7/1

N2 - Imatinib at 400 mg daily is effective in chronic-phase chronic myeloid leukemia (CML) after interferon failure, although only a few patients achieve a molecular remission. We investigated whether higher doses of imatinib may be more effective. Thirty-six patients with chronic-phase CML after failure on interferon-α were treated with 400 mg imatinib twice daily. Median time from diagnosis was 25 months (range, 10-135 months); 4 patients (11%) had clonal evolution. All 11 patients with active disease achieved complete hematologic response. Excluding patients with fewer than 35% Ph-positive metaphases before the start of therapy, 19 (90%) of 21, evaluable patients achieved a major cytogenetic response. Of 27 evaluable patients, 24 (89%) achieved a complete cytogenetic response. Quantitative polymerase chain reaction was performed in bone marrow every 3 months. Of 32 evaluable patients, 18 (56%) showed BCR-ABL/ABL percentage ratios lower than 0.045%, including 13 (41%) with undetectable levels. With a median follow-up of 15 months, all patients were alive in chronic phase. Toxicities were similar to those reported with standard dose; 71% of patients continue to receive 600 mg or more of imatinib daily. In conclusion, high-dose imatinib induces complete cytogenetic responses, in most patients with chronic-phase CML after interferon failure. This is accompanied by a high rate of molecular remission.

AB - Imatinib at 400 mg daily is effective in chronic-phase chronic myeloid leukemia (CML) after interferon failure, although only a few patients achieve a molecular remission. We investigated whether higher doses of imatinib may be more effective. Thirty-six patients with chronic-phase CML after failure on interferon-α were treated with 400 mg imatinib twice daily. Median time from diagnosis was 25 months (range, 10-135 months); 4 patients (11%) had clonal evolution. All 11 patients with active disease achieved complete hematologic response. Excluding patients with fewer than 35% Ph-positive metaphases before the start of therapy, 19 (90%) of 21, evaluable patients achieved a major cytogenetic response. Of 27 evaluable patients, 24 (89%) achieved a complete cytogenetic response. Quantitative polymerase chain reaction was performed in bone marrow every 3 months. Of 32 evaluable patients, 18 (56%) showed BCR-ABL/ABL percentage ratios lower than 0.045%, including 13 (41%) with undetectable levels. With a median follow-up of 15 months, all patients were alive in chronic phase. Toxicities were similar to those reported with standard dose; 71% of patients continue to receive 600 mg or more of imatinib daily. In conclusion, high-dose imatinib induces complete cytogenetic responses, in most patients with chronic-phase CML after interferon failure. This is accompanied by a high rate of molecular remission.

UR - http://www.scopus.com/inward/record.url?scp=10744231480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744231480&partnerID=8YFLogxK

U2 - 10.1182/blood-2003-01-0025

DO - 10.1182/blood-2003-01-0025

M3 - Article

C2 - 12637317

AN - SCOPUS:10744231480

VL - 102

SP - 83

EP - 86

JO - Blood

JF - Blood

SN - 0006-4971

IS - 1

ER -